Bayerische Motoren Werke ADR (BMWYY)

As of December 18, 2025, the landscape of the global automotive industry is undergoing a seismic shift, and at the center of this transformation stands the newly restructured Tata Motors ecosystem. Known formally as Tata Motors Limited (NSE: TATAMOTORS | BSE: 500570), the company has recently completed one of the most significant corporate restructuring exercises [...]

As of December 17, 2025, QuantumScape Corporation (NYSE: QS), soon to be listed on Nasdaq from December 23, 2025, stands as a prominent innovator in the electric vehicle (EV) battery sector. Headquartered in San Jose, California, the company is singularly focused on the development and commercialization of next-generation solid-state lithium-metal batteries. QuantumScape’s ambition is to [...]

MIAMI, FL - In an industry where car accidents often lead to logistical chaos, Auto Body Lab is officially setting a new standard for automotive recovery in South Florida. Operating as a premier distributor of comprehensive collision repair and paint services, Auto Body Lab ( https://autobodylab.com/ ) bridges the gap between distressed drivers and elite, certified restoration solutions.

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of the ACA tax credits that were at the heart of the recent government shutdown. This bill now heads to the Senate for consideration.

HealthLynked (OTCQB: HLYK) announced a strategic consulting partnership with PBACO Holding LLC, a physician-led, value-based care organization supporting more than 15,000 physicians across 26 states and managing over 400,000 patient lives. The partnership is intended to strengthen HealthLynked’s integration with large insurance payers and accelerate deployment of its AI-enabled care-coordination platform by leveraging PBACO’s expertise in value-based contracting, commercial and government ACO program design, payer relationships, and multi-state provider network operations.

Oncotelic Therapeutics (OTCQB: OTLC ) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (“SABCS”), highlighting that its Deciparticle(TM) platform can package even the toughest, water-resistant drugs into smaller, uniform nanoparticles that are small enough for effective and safe intravenous use ( ibn.fm/LxQ7N ).

Immunotherapy, an approach that seeks to stimulate the immune system to attack and destroy cancer cells, is a new field of research that has shown remarkable results in some patients. However, the overall fraction of patients who can benefit from immunotherapy is still very low, and researchers have been looking for ways to make this treatment modality work for a lot more patients.

As of December 12, 2025, Plug Power Inc. (NASDAQ: PLUG) stands as a pivotal player in the burgeoning green hydrogen economy, dedicated to developing comprehensive hydrogen fuel cell and electrolyzer systems. The company's strategic focus extends beyond the mere manufacturing of fuel cells to orchestrating an entire hydrogen value chain, encompassing production, liquefaction, storage, transport, [...]

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation of the investigational therapy, underscoring the potential of SGX302 as a noncarcinogenic, photodynamic treatment.

Date: 12/11/2025 1. Introduction QuantumScape Corporation (NYSE: QS, soon to be Nasdaq: QS), headquartered in San Jose, California, stands at the forefront of developing next-generation solid-state lithium-metal battery technology. As of December 11, 2025, the company remains a significant focal point in the market due to its advanced technological breakthroughs, strategic milestones, and the transformative [...]

Date: December 11, 2025 1. Introduction Qualcomm (NASDAQ: QCOM), headquartered in San Diego, California, stands as a foundational technology leader in the wireless industry. The company designs semiconductors, software, and services critical to global mobile communication standards, including 5G and 4G. As of December 2025, Qualcomm is in the midst of a significant strategic transformation, [...]

Plug Power stock has performed poorly over the past few years, but that could change soon.

As the final weeks of 2025 unfold, the German equity market finds itself at a critical crossroads. While current industrial production figures remain sluggish, a wave of forward-looking optimism is sweeping through the financial district in Frankfurt. Leading the charge is European brokerage powerhouse Kepler Cheuvreux, which has just released

A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin exposure, positioning the company’s work at the center of biodefense preparedness as public awareness of ricin’s lethality grows.

Annovis Bio (NYSE: ANVS) announced it will initiate an open-label extension study in January 2026 to further evaluate the long-term safety and efficacy of buntanetap in patients with Parkinson disease. The study will provide continued access to buntanetap for participants from prior clinical trials while enabling extended monitoring of safety outcomes, sustained effects on motor and cognitive function, and the collection of biomarker data to support further evaluation of buntanetap’s potential as a disease-modifying therapy for neurodegenerative disorders.

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced computing, and cybersecurity technologies that may support Nutriband’s research and long-term product development initiatives. The company said the discussions will focus on areas such as secure AI and analytics platforms for regulated pharmaceutical data, data integrity frameworks supporting abuse-deterrent technologies, and advanced modeling and simulation enabled by quantum-ready infrastructure, while emphasizing that the LOI does not establish a partnership or commercial relationship and that any future collaboration would be subject to further review, due diligence, and definitive agreements.

As 2025 draws to a close, the artificial intelligence investment landscape has undergone a profound transformation. The "generative hype" of previous years has matured into a disciplined focus on the infrastructure of trust and the physical manifestation of intelligence. This shift is most visible in the surge of specialized Exchange-Traded Funds (ETFs) targeting AI Security [...]

As 2025 draws to a close, the global financial landscape has been fundamentally reshaped by what analysts are calling the "Gold and Silver Revolution." In a year marked by geopolitical volatility and a tectonic shift in industrial demand, precious metals have staged a historic rally that has left traditional equity

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human Services. For a long time, the scientific community has struggled to find out why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid. Now a new study has established that the key driver among people with long Covid could be chronic inflammation and this opens new pathways to treating the condition .

The automotive industry has reached a definitive tipping point as of late 2025. The era of the internal combustion engine’s mechanical complexity has been superseded by a new era of silicon-driven sophistication. We are no longer witnessing the evolution of the car; we are witnessing the birth of the "Software-Defined Vehicle" (SDV), where the value [...]

In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.

In a pivotal move set to redefine the landscape of artificial intelligence in the automotive sector, leading research and development organizations, imec and Japan's Advanced SoC Research for Automotive (ASRA), are spearheading a collaborative effort to standardize chiplet designs for advanced automotive AI applications. This strategic partnership addresses a critical need for interoperability, scalability, and [...]

A new study done in India has produced results that bring into question the longstanding assumption that treating cancer requires tumors to be destroyed. The researchers attained remarkable results by using another approach, treating the tumor rather than attacking it, and their approach was effective in taming the aggressiveness of glioblastoma while also toning down many biomarkers that indicate the severity of the cancer.

The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates fall to just 3% . These economics have created a bottleneck that leaves patients waiting years for new treatments that rarely arrive.

The pre-owned vehicle industry in Riverside is experiencing a shift as TM Motors redefines what buyers should expect from their car-purchasing experience. Located at 10100 Arlington Ave., the dealership has built a reputation for prioritizing customer satisfaction over high-pressure sales tactics, creating a welcoming environment for those seeking quality transportation options.